Division of General Thoracic Surgery, Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 1608582, Japan.
Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Kofu, Yamanashi 4008506, Japan.
Int J Mol Sci. 2019 Mar 22;20(6):1461. doi: 10.3390/ijms20061461.
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. Despite the increasing research interest in the pathogenesis of IPF, unfavorable survival rates remain associated with this condition. Recently, novel therapeutic agents have been shown to control the progression of IPF. However, these drugs do not improve lung function and have not been tested prospectively in patients with IPF and coexisting lung cancer, which is a common comorbidity of IPF. Optimal management of patients with IPF and lung cancer requires understanding of pathogenic mechanisms and molecular pathways that are common to both diseases. This review article reflects the current state of knowledge regarding the pathogenesis of pulmonary fibrosis and summarizes the pathways that are common to IPF and lung cancer by focusing on the molecular mechanisms.
特发性肺纤维化(IPF)定义为一种特定类型的慢性、进行性纤维性间质性肺炎,原因不明,主要发生于老年人,病变局限于肺部。尽管人们对 IPF 的发病机制越来越感兴趣,但与这种疾病相关的存活率仍然较差。最近,新型治疗药物已被证明可控制 IPF 的进展。然而,这些药物并不能改善肺功能,也没有在前瞻性研究中在同时患有 IPF 和肺癌的患者中进行测试,肺癌是 IPF 的常见合并症。对同时患有 IPF 和肺癌的患者进行最佳管理需要了解两种疾病共有的发病机制和分子途径。这篇综述文章反映了目前关于肺纤维化发病机制的知识状况,并通过关注分子机制,总结了 IPF 和肺癌共有的途径。